Where this information about bisphosphonates comes from
This page tells you about the major sources of information that we use to put together this section.
All our information is checked by cancer specialists. The names of our specialist reviewers are at the end of this list. We also try to find patients to review all our sections. If you have had bisphosphonates, live in the UK and would like to become a patient reviewer, you can write to us by clicking on the 'contact us' button on the right hand side of this page.
Electronic Medicines Compendium
British National Formulary
National Institute of Clinical Excellence Guidelines
Scottish Intercollegiate Guidelines Network
National Cancer Institute - USA
PubMed Central - National Institute of Health Medical Archive of Science Literature
Handbook of Cancer Chemotherapy (8th edition)
Skeel RT and Khleif SN
Lippincott Williams and Wilkins, 2011
Principles and practice of oncology (8th edition)
De Vita VT, Hellman S and Rosenberg SA
Lippincott, Williams and Wilkins, 2008
Reviews and articles
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Michael Pazianas, Cyrus Cooper, F Hal Ebetino, R Graham G Russell. Therapeutics and Clinical Risk Management
Bisphosphonates in multiple myeloma. (Cochrane review). R Mhaskar, J Redzepovic, K Wheatley, OAC Clark, B Miladinovic, A Glasmacher, A Kumar, B Djulbegovic B. Database of Systematic Reviews 2012, Issue 5. Art. No.: CD003188. DOI: 10.1002/14651858.CD003188.
Emerging role of bisphosphonates in the clinic - anti tumor activity and prevention of metastasis to bone. Lipton A. Cancer Treatment Review. 2008;34 Suppl 1:S25-30.
Zoledronic acid in the management of metastatic bone disease. Polascik TJ, Mouraviev V. Therapeutic Clinical Risk Managagement. 2008 Feb;4(1):261-8.
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Cancer. 2008 Jul 1;113(1):193-201.
Bisphosphonates and other bone agents for breast cancer. (Cochrane review). Wong MHF, Stockler MR, Pavlakis N. Database of Systematic Reviews 2012, Issue 2. Art. No.: CD003474. DOI: 10.1002/14651858.CD003474.pub3.
Bisphosphonates for advanced prostate cancer. (Cochrane review). KK Yuen, M Shelley, WM Sze, TJ Wilt, M Mason. Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006250. DOI: 10.1002/14651858.CD006250.
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Migliorati Prof. Cesar A, Siegel Prof Michael A, and Elting Prof Linda S. Lancet Oncology, Volume 7, Issue 6, June 2006, Pages 508-514.
Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Costa L, Lipton A, Coleman RE. Supportive Cancer Therapy. 2006 Apr 1;3(3):143-53.
Ms Debbie Wright
We would like to thank the pharmaceutical manufacturers who have answered our questions during the compilation of this information.
Question about cancer? Contact our information nurse team